Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis
- PMID: 2087873
- DOI: 10.1016/0264-410x(90)90002-4
Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis
Abstract
Both leprosy and tuberculosis present continuing problems in their control, especially in the developing world, despite the availability of drugs effective in producing a bacteriological cure. Improved immunoprophylaxis, and an effective immunotherapy to be used with chemotherapy are urgently required. Intradermal injection of a suspension of killed Mycobacterium vaccae promotes cell-mediated responses to antigens common to all mycobacteria, and switches off the tissue-necrotizing aspects of the Koch phenomenon. These properties led to the use of the suspensions as an improved vaccine, either alone or in combination with BCG. The same properties led to the employment of the suspension in immunotherapy as an adjunct to chemotherapy in the treatment of both leprosy and tuberculosis. The evidence leading to these conclusions is reviewed and discussed.
Similar articles
-
Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis.Front Biosci. 2004 May 1;9:1701-19. doi: 10.2741/1292. Front Biosci. 2004. PMID: 14977580 Review.
-
Immunotherapy and immunoprophylaxis of leprosy.Lepr Rev. 1983 Jun;Spec No:47-60. doi: 10.5935/0305-7518.19830048. Lepr Rev. 1983. PMID: 6350772 Review. No abstract available.
-
Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis.Int J Lepr Other Mycobact Dis. 1989 Mar;57(1):45-53. Int J Lepr Other Mycobact Dis. 1989. PMID: 2659701
-
Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.Lancet. 1996 Jul 6;348(9019):17-24. Lancet. 1996. PMID: 8691924 Clinical Trial.
-
[The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis].Zhonghua Jie He He Hu Xi Za Zhi. 2001 Jan;24(1):43-7. Zhonghua Jie He He Hu Xi Za Zhi. 2001. PMID: 11802939 Clinical Trial. Chinese.
Cited by
-
Rapidly Growing Mycobacterium Species: The Long and Winding Road from Tuberculosis Vaccines to Potent Stress-Resilience Agents.Int J Mol Sci. 2021 Nov 29;22(23):12938. doi: 10.3390/ijms222312938. Int J Mol Sci. 2021. PMID: 34884743 Free PMC article. Review.
-
Cost-effectiveness of incorporating Mycobacterium indicus pranii vaccine to multidrug therapy in newly diagnosed leprosy cases for better treatment outcomes & immunoprophylaxis in contacts as leprosy control measures for National Leprosy Eradication Programme in India.Indian J Med Res. 2021 Jul;154(1):121-131. doi: 10.4103/ijmr.IJMR_661_20. Indian J Med Res. 2021. PMID: 34782538 Free PMC article.
-
Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis.Front Immunol. 2020 Sep 9;11:557809. doi: 10.3389/fimmu.2020.557809. eCollection 2020. Front Immunol. 2020. PMID: 33013927 Free PMC article. Review.
-
MULTIDRUG RESISTANT TUBERCULOSIS - BIOMECHANISM, EPIDEMIOLOGY AND MANAGEMENT STRATEGIES.Med J Armed Forces India. 1997 Jul;53(3):207-213. doi: 10.1016/S0377-1237(17)30717-7. Epub 2017 Jun 26. Med J Armed Forces India. 1997. PMID: 28769486 Free PMC article. Review.
-
Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis.PLoS One. 2011;6(9):e23826. doi: 10.1371/journal.pone.0023826. Epub 2011 Sep 6. PLoS One. 2011. PMID: 21909406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical